Evidence-Based Complementary and Alternative Medicine / 2014 / Article / Tab 5

Research Article

A Metabonomics Profiling Study on Phlegm Syndrome and Blood-Stasis Syndrome in Coronary Heart Disease Patients Using Liquid Chromatography/Quadrupole Time-of-Flight Mass Spectrometry

Table 5

Plasma differential metabolites for discriminating phlegm from blood-stasis syndrome.

Mode RT Mass MetaboliteVIP aFold

EIS+1.21 131.10 L-Leucine1.83 −0.62
1.02 168.03 Uric acid1.73 −1.32
2.00 165.08 L-Phenylalanine1.68 −0.37
3.82 204.09 L-Tryptophan1.62 −0.26
10.94 250.12 Ubiquinone 1.57 −0.81
15.21 384.29 17,20-dimethyl prostaglandin F1α1.57 0.75
3.82 145.05 Isoquinoline N-oxide1.55 −0.26
10.96 393.29 PGH2-EA1.54 0.43
17.48 283.29 Stearamide1.54 −1.71
11.74 568.33 Deoxycholic acid 3-glucuronide1.52 0.88
16.85 368.29 Octadecyl fumarate1.50 1.10

EIS10.28 250.12 Ubiquinone2.70 −1.15
17.23 363.24 N-Palmitoyl taurine2.58 −2.33
17.46 389.26 N-Oleoyl taurine2.57 −1.95
16.68 552.19 Deoxycholic acid disulfate2.26 −2.08
1.08 181.07 L-Tyrosine1.76 0.56
1.03 244.07 Uridine1.70 −0.28
0.74 130.03 Itaconic acid1.68 1.44
1.04 308.04 Deoxyuridine monophosphate (dUMP)1.63 −1.04
16.75 330.26 Eicosapentaenoic acid ethyl ester1.63 4.77

Fold = log2(average peak intensity of phlegm syndrome/average peak intensity of blood stasis syndrome); “−” represented downregulated compared to blood stasis syndrome; “+” represented upregulated compared to blood stasis syndrome.